TrialThe Journal of biological chemistry2013

The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.

Jiro Kikuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.